[go: up one dir, main page]

NO20002217D0 - Cyclopentan-heptansyre, 2-heteroarylalkenylderivater som terapeutiske midler - Google Patents

Cyclopentan-heptansyre, 2-heteroarylalkenylderivater som terapeutiske midler

Info

Publication number
NO20002217D0
NO20002217D0 NO20002217A NO20002217A NO20002217D0 NO 20002217 D0 NO20002217 D0 NO 20002217D0 NO 20002217 A NO20002217 A NO 20002217A NO 20002217 A NO20002217 A NO 20002217A NO 20002217 D0 NO20002217 D0 NO 20002217D0
Authority
NO
Norway
Prior art keywords
cyclopentane
therapeutic agents
heptanoic acid
heteroarylalkenyl derivatives
heteroarylalkenyl
Prior art date
Application number
NO20002217A
Other languages
English (en)
Other versions
NO20002217L (no
Inventor
Robert M Burk
Original Assignee
Allergan Sales Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Sales Inc filed Critical Allergan Sales Inc
Publication of NO20002217D0 publication Critical patent/NO20002217D0/no
Publication of NO20002217L publication Critical patent/NO20002217L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/28—Halogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0016—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing only hydroxy, etherified or esterified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0041—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing nitrogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/005—Analogues or derivatives having the five membered ring replaced by other rings
    • C07C405/0058—Analogues or derivatives having the five membered ring replaced by other rings having the side-chains or their analogues or derivatives attached to a not condensed ring different from a five-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
NO20002217A 1997-11-19 2000-04-28 Cyclopentan-heptansyre, 2-heteroarylalkenylderivater som terapeutiske midler NO20002217L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/974,067 US6124344A (en) 1993-12-28 1997-11-19 Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
PCT/US1998/024481 WO1999025358A1 (en) 1997-11-19 1998-11-17 Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents

Publications (2)

Publication Number Publication Date
NO20002217D0 true NO20002217D0 (no) 2000-04-28
NO20002217L NO20002217L (no) 2000-07-18

Family

ID=25521544

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20002217A NO20002217L (no) 1997-11-19 2000-04-28 Cyclopentan-heptansyre, 2-heteroarylalkenylderivater som terapeutiske midler

Country Status (12)

Country Link
US (3) US6124344A (no)
EP (1) EP1032395A1 (no)
JP (1) JP2001522893A (no)
KR (1) KR20010024653A (no)
CN (1) CN1291100A (no)
AU (1) AU1461699A (no)
BR (1) BR9814679A (no)
CA (1) CA2310630A1 (no)
NO (1) NO20002217L (no)
NZ (1) NZ504191A (no)
RU (1) RU2217145C2 (no)
WO (1) WO1999025358A1 (no)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6124344A (en) * 1993-12-28 2000-09-26 Allergan Sales, Inc. Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
ES2232434T3 (es) 1999-03-05 2005-06-01 Duke University Analogos de prostaglandinas c-16 fp selectivas insaturadas.
US6894175B1 (en) 1999-08-04 2005-05-17 The Procter & Gamble Company 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
US6395787B1 (en) * 2000-02-08 2002-05-28 Allergan Sales, Inc. Ocular hypotensive lipids
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
KR100437873B1 (ko) * 2001-05-08 2004-06-26 연성정밀화학(주) 프로스타글란딘 유도체의 제조방법 및 그의 입체특이적출발물질
US7351404B2 (en) * 2002-02-04 2008-04-01 Allergan, Inc. Method of enhancing hair growth
US9216183B2 (en) 2002-02-04 2015-12-22 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
US8758733B2 (en) 2002-02-04 2014-06-24 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
EP1527781B1 (en) * 2002-08-09 2008-07-23 Taisho Pharmaceutical Co., Ltd Antipruritic agent
US7737182B2 (en) 2002-08-09 2010-06-15 Taisho Pharmaceutical Co., Ltd. Pharmaceuticals for xerosis
WO2004043471A1 (ja) * 2002-11-13 2004-05-27 Taisho Pharmaceutical Co., Ltd. 鎮痒剤
JP2005511607A (ja) * 2003-07-10 2005-04-28 アラーガン、インコーポレイテッド ＥＰ２受容体作動剤としてのω−シクロアルキル１７−ヘテロアリールプロスタグランジンＥ２類似体
JP4666257B2 (ja) 2003-07-25 2011-04-06 小野薬品工業株式会社 軟骨関連疾患治療剤
US7183310B2 (en) * 2004-08-10 2007-02-27 Allergan, Inc. Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US7101904B2 (en) * 2004-08-10 2006-09-05 Allergan, Inc. Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US7906552B2 (en) * 2004-08-10 2011-03-15 Allergan, Inc. Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents
CN101237885B (zh) 2005-06-03 2011-01-19 小野药品工业株式会社 神经再生和/或保护剂
DK1960353T3 (da) * 2005-11-03 2014-05-26 Allergan Inc Prostaglandiner og analoger som midler til sænkning af intraokulært tryk
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
CA2724340A1 (en) * 2008-05-14 2009-11-19 Peter Thomas Roth Labs, Llc Prostaglandin based compositions and method of use thereof
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
JP2012507552A (ja) 2008-10-29 2012-03-29 アエリエ・ファーマシューティカルズ・インコーポレーテッド プロスタグラジンのアミノ酸塩
US8623918B2 (en) 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8722739B2 (en) 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US20100204335A1 (en) * 2008-12-01 2010-08-12 Allergan, Inc. Kit and composition for eyelash growth
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
ES2834451T3 (es) 2009-05-01 2021-06-17 Aerie Pharmaceuticals Inc Inhibidores de mecanismo doble para el tratamiento de enfermedades
US8952051B2 (en) * 2009-11-05 2015-02-10 Allergan, Inc. Ophthalmic formulations containing substituted gamma lactams and methods for use thereof
US9149484B2 (en) 2009-11-09 2015-10-06 Allergan, Inc. Compositions and methods for stimulating hair growth
AU2010314990B2 (en) 2009-11-09 2015-10-01 Allergan, Inc. Compositions and methods for stimulating hair growth
US8783923B2 (en) * 2010-03-18 2014-07-22 Chung Yuan Christian University Auto lamp structure
US8859616B2 (en) 2011-01-21 2014-10-14 Allergan, Inc. Compounds and methods for enhancing hair growth
EP2968668B1 (en) * 2013-03-15 2019-07-03 Allergan, Inc. Prostamide-containing intraocular implant
PT3811943T (pt) 2013-03-15 2023-03-15 Aerie Pharmaceuticals Inc Composto para uso no tratamento de distúrbios oculares
CN105188666A (zh) 2013-04-01 2015-12-23 阿勒根公司 用于持续的眼内释放的微球药物递送系统
EP2983663B1 (en) * 2013-04-12 2020-01-22 Allergan, Inc. Sustained release of bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction
ES2805880T3 (es) 2013-10-31 2021-02-15 Allergan Inc Implantes intraoculares que contienen prostamida y métodos de uso de éstos
BR112016013594A8 (pt) * 2013-12-13 2020-05-19 Allergan Inc formas cristalinas de um composto dihidroxi ciclopentil alfa, ômega-dissubstituído, composição farmacêutica, métodos para o preparo e uso das mesmas
BR112017023316A2 (pt) 2015-04-30 2018-08-14 Allergan, Inc. método cosmético e uso terapêutico para redução de gordura
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
US11389441B2 (en) 2016-08-31 2022-07-19 Aerie Pharmaceuticals, Inc. Ophthalmic compositions
JP2020515583A (ja) 2017-03-31 2020-05-28 アエリエ ファーマシューティカルズ インコーポレイテッド アリールシクロプロピル−アミノ−イソキノリニルアミド化合物
AU2019337703B2 (en) 2018-09-14 2023-02-02 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
US12004995B2 (en) 2020-07-21 2024-06-11 Allergan, Inc. Intraocular implant with high loading of a prostamide

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834498A (en) * 1992-09-21 1998-11-10 Allergan Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
RU2067094C1 (ru) * 1993-09-27 1996-09-27 Владимир Виленович Безуглов 1,3-динитроглицериновые эфиры полиненасыщенных жирных кислот, гидроксипроизводных полиненасыщенных жирных кислот и простагландинов и способы их получения
US5545665A (en) * 1993-12-28 1996-08-13 Allergan Cyclopentane(ene) heptenoic or heptanoic acids and derivatives thereof useful as therapeutic agents
US6124344A (en) * 1993-12-28 2000-09-26 Allergan Sales, Inc. Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
EP0825980B1 (en) * 1995-05-18 2001-07-04 Allergan Sales, Inc. Cyclopentane heptan(ene)oic acid, 2-heteroarylakenyl derivatives as therapeutic agents for the treatment of ocular hypertension
US5741810A (en) * 1996-02-29 1998-04-21 Allergan Cyclopentane heptan(ene)oic acid, 2- heteroarylalkenyl derivatives as therapeutic agents

Also Published As

Publication number Publication date
RU2217145C2 (ru) 2003-11-27
US6160129A (en) 2000-12-12
CN1291100A (zh) 2001-04-11
US6248773B1 (en) 2001-06-19
AU1461699A (en) 1999-06-07
NO20002217L (no) 2000-07-18
CA2310630A1 (en) 1999-05-27
EP1032395A1 (en) 2000-09-06
JP2001522893A (ja) 2001-11-20
KR20010024653A (ko) 2001-03-26
WO1999025358A1 (en) 1999-05-27
NZ504191A (en) 2002-12-20
BR9814679A (pt) 2000-10-03
US6124344A (en) 2000-09-26

Similar Documents

Publication Publication Date Title
NO20002217D0 (no) Cyclopentan-heptansyre, 2-heteroarylalkenylderivater som terapeutiske midler
DK1028961T3 (da) Pleuromutilinderivater som antimikrobielle midler
DK1212327T3 (da) Pyrazolopyrimidiner som terapeutiske midler
ATE248812T1 (de) Arylsulfonylhydroxamsäurederivate
DK1003720T3 (da) Aryloxyarylsulfonylaminohydroxamsyrederivater
NO20015477D0 (no) 4,5,6,7-tetrahydroindazol-derivater som anti-tumor midler
TR199802289A3 (tr) Fosfonasit-ikame etmis benzazepinon-n-asetikasit türevleri.
NO20013671L (no) Substituerte bisycliske derivater nyttige som anticancer midler
NO20014412L (no) Forbindelser nyttige som anti-inflammatoriske midler
IS2071B (is) Ný 3-arýl-2-hýdroxýprópíonsýruafleiða (I)
DK1538160T3 (da) Substituerede isochinolin-3-carboxylsyreamider, deres fremstilling og deres anvendelse som lægemiddel
IS2277B (is) Meðferðarlegar bíarýl afleiður
NO984106D0 (no) Azolobenzazepin-derivater som neurologisk aktive midler
DK0975623T3 (da) Indazolamidforbindelser som sertoninerge midler
ATE212635T1 (de) 1,3,8-triazaspiro(4,5)decan-4-on-derivate
IS5562A (is) Nýjar díhýdroxýhexanósýru afleiður
NO20012965D0 (no) Sulfonyloksazolaminer som terapeutisk aktive forbindelser
DK0747346T3 (da) N-acyl-2-arylcyclopropylmethylaminderivater som melatonerge midler
DK0799223T3 (da) Piperidineddikesyrederivater til anvendelse som fibrinogenantagonistmidler
DK1075471T3 (da) Idolylderivater som serotonerge midler
NO20000434D0 (no) Lyksofuranosyl benzimidazoler som antivirale midler
NO994386D0 (no) 2-substituerte benzoylcykloalkyl-1-karboksylsyrederivater
NO20002321D0 (no) Bifenylderivater som farmasøytiske midler
NO996244D0 (no) Pyrrolidinkarboksylsyrederivater som endotelinantagonister
DK1073651T3 (da) Indolylderivater som serotonerge midler